GSK Plc is in talks to buy biotech company IDRx, people with knowledge of the matter said, a deal that would see the British ...

GSK (GSK) stock is in focus as the company is nearing a $1B deal to acquire IDRx, a private biotech focused on a rare ...

GSK (GSK) is in advanced discussions to purchase privately-owned U.S. biotech IDRx, which is working on a treatment for rare gastrointestinal ...

--Pharmaceutical giant GSK PLC is in talks to buy U.S. privately owned biotech company IDRx, which is developing a treatment for rare gastrointestinal tumors, for up to $1 billion, the Financial Times ...

GSK is reportedly in late-stage negotiations about a $1 billion deal to acquire IDRx and its experimental targeted therapy ...

As top pharma executives arrive in San Francisco, CA, to attend the J.P. Morgan Healthcare Conference next week, biotech ...

Outside the FTSE 350, a big downwards mover is RBG Holdings PLC (AIM:RBGP), the holding company for law firms Rosenblatt and Memery Crystal.

Scorpion’s drug candidate inhibits a mutation that is a major driver of breast, gynaecological and head and neck cancers ...

Results from that are due in the second half of 2024. GSK is reportedly in negotiations about a $1bn deal to acquire IDRx and its targeted therapy for a form of rare gastrointestinal tumour.

In a report released on January 9, David Evans from Kepler Capital maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a ...

In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other FTSE dividend stocks. Goldman Sachs Research predicts moderate growth for the UK economy in 2025 ...

We recently compiled a list of the 10 Best FTSE Dividend Stocks To Buy Now. In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other FTSE dividend stocks.